Background: The 2024 International Myeloma Society–International Myeloma Working Group consensus classifies elevated β2-microglobulin (β2M) with normal serum creatinine (SCr) as high-risk multiple myeloma (MM). However, creatinine-based renal definitions may be inaccurate in Asian populations with lower muscle mass.Aims: To evaluate the prognostic impact of isolated elevated β2M on overall survival (OS) using SCr– and creatinine clearance (CrCl)-based definitions of renal function.Methods: This retrospective study included newly diagnosed MM patients (2006–2023). Patients were classified as Group A (β2M ≤5.5 mg/L), Group B (β2M >5.5 mg/L, SCr 5.5 mg/L, SCr ≥1.2 mg/dL). In secondary analyses, renal function was redefined using CrCl (≥60 mL/min).Results: Among 250 patients (mean age 61.0±12.1 years; 62.0% male), 34.4% underwent autologous stem cell transplantation. Groups A, B, and C included 110 (44.0%), 29 (11.6%), and 111 (44.4%) patients, respectively. At a median follow-up of 4.6 years, 4-year OS for Groups A, B, and C was 80.0%, 71.6%, and 59.5% (P=0.009). Group B did not demonstrate significantly inferior OS compared with Group A (adjusted hazard ratio [aHR], 1.53; 95% CI, 0.71–3.28), whereas Group C had significantly worse OS (aHR, 1.86; 95% CI, 1.16–3.00). When renal function was defined by CrCl, reclassified Group B (n=19) showed significantly inferior OS (aHR, 2.42; 95% CI, 1.07–5.45).Conclusions: Elevated β2M with normal SCr failed to show independent prognostic significance in this cohort. However, CrCl-based definitions improved prognostic stratification, suggesting that standard creatinine thresholds may underestimate risk in Thai patients.